NCT06315634
Intrathecal Dexmedetomidine vs Midazolame
Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries
National Cancer Institute, Egypt·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Postoperative Pain
- Drug/Device/Intervention
- Dexmedetomidine
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- National Cancer Institute, Egypt
- Location
- Cairo, Egypt
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Mar 15, 2021
- End date
- Mar 10, 2022
- Enrollment
- 75 participants
Primary outcome
Duration of sensory block
Summary
Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine
 Versus Midazolame in Orthopedic Cancer Surgeries
ICD-10 classifications
Acute painPostoperative intestinal obstructionPain, unspecifiedDuring surgical operationDuring surgical operation
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06315634
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06315634 through Pure Global AI's free database. This Phase 4 trial is sponsored by National Cancer Institute, Egypt and is currently Completed. The study focuses on Postoperative Pain. Target enrollment is 75 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.